Home clinical
 

Keywords :   


Tag: clinical

Presage Biosciences In-Licenses Clinical Stage Drug Program

2015-12-02 02:08:44| drugdiscoveryonline Home Page

Presage Biosciences, an oncology company pioneering a radical new drug development approach that incorporates human efficacy data much earlier in development and clinical trials, announced recently that it has in-licensed voruciclib, its first clinical stage drug program

Tags: program stage drug clinical

 

Mipsagargin Demonstrates Clinical Benefit In Subset Of Glioblastoma Patients

2015-12-02 02:02:20| drugdiscoveryonline Home Page

GenSpera Inc., a biotech company developing a novel prodrug therapeutic for the treatment of cancer, recently announced results from the Phase II study investigating the use of mipsagargin (G-202) for the treatment of glioblastoma multiforme

Tags: benefit patients clinical demonstrates

 
 

NASH Clinical Trail Surpasses 25% Patient Recruitment Milestone

2015-11-18 20:49:12| Agriculture - Topix.net

Australian biopharmaceutical Company Immuron Limited is pleased to announce that the Company's Phase IIb, the IMM-124E clinical trial for the treatment of NASH , has successfully passed its 25% recruitment milestone with 35 patients having been successfully randomized into either arms. Immuron continues to drive its NASH clinical trial recruitment to meet its enrollment goal of 120 biopsy-proven NASH subjects by June 2016.

Tags: patient clinical trail recruitment

 

Merck to Release Findings from Integrated Analysis of Six Phase 2 and 3 Clinical Trials Evaluating Investigational Elbasvir/Grazoprevir in Patients with Chronic Hepatitis C Genotype 1, 4 or 6 Infection and Compensated Cirrhosis at The Liver Meeting

2015-11-15 01:00:00| Merck.com - Research & Development News

Dateline City: KENILWORTH, N.J. Patients with Compensated Liver Cirrhosis Among Most Difficult-to-Treat KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the presentation of results from an integrated analysis of patients with compensated liver cirrhosis (Child-Pugh class A) from six Phase 2 and 3 clinical trials evaluating the efficacy and safety of the investigational once-daily tablet elbasvir/grazoprevir1 (50mg/100mg) with or without ribavirin (RBV) in patients with chronic hepatitis C virus (HCV) genotypes (GT) 1, 4 or 6 infection. Language: English Contact: MerckMedia:Doris Li, 908-246-5701orSarra Herzog, 201-669-6570orInvestors:Teri Loxam, 908-740-1986orJustin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: the or at release

 

Galena Biopharma to Present Final GALE-401 Phase 2 Clinical Data at...

2015-11-06 19:09:55| Biotech - Topix.net

Galena Biopharma to Present Final GALE-401 Phase 2 Clinical Data at the 57th American Society of Hematology Annual Meeting and Exposition SAN RAMON, Calif., Nov. 6, 2015 -- Galena Biopharma, Inc. , a biopharmaceutical company developing and commercializing innovative, targeted oncology therapeutics that address major medical needs across the full spectrum of cancer care, today announced the final data from the Company's GALE-401 Phase 2 proof-of-concept clinical trial will be presented at the upcoming 57th American Society of Hematology Annual Meeting and Exposition in Orlando, FL.

Tags: at data present final

 

Sites : [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] next »